Overview

Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds

Status:
Recruiting

Trial end date:
2022-06-20

Target enrollment:

Participant gender:

Summary

This is a Phase I, double-blind, placebo-controlled, randomized first-in-human study including healthy volunteers with acute epidermal wounds formed by the suction blister technique designed to evaluate the safety, tolerability, and potential systemic exposure of multiple topical doses of TCP-25.

Phase:

Phase 1

Details

Lead Sponsor:

Xinnate AB

Collaborator:

Region Skane